Clinical Trial Update: A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease [Phase 2]

View source ↗

Summary

The document reports a Phase 2 clinical trial evaluating Zasocitinib (TAK-279) in adults with active Crohn's disease. The study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Zasocitinib (TAK-279) (zasocitinib)

Snippet

Sponsor: Takeda | Conditions: Crohn's Disease | Phase 2 | Status: NOT_YET_RECRUITING